Stories about Injection (medicine)

Subscribe to topic

Subscribe to Injection (medicine)

17.09.2019 – 18:00
Senzer Limited
Senzer's Medical Device Approved in Europe for the Safe and Effective Delivery of Cannabinoids
London (ots/PRNewswire) - Senzer Pharmaceuticals has been granted a CE Mark that certifies its inhaler as a medical device, allowing it to now be available for patients in Europe for the 'safe and effective delivery of pharmaceutical cannabinoids.' The Class IIa Medical Device approval is the first-ever in the cannabinoid space and clears the way for the UK-based ...
more
24.06.2019 – 14:00
Merck KGaA
Merck to Showcase New Data Across MS Portfolio at EAN 2019
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK or U.S. based media - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...
more
30.04.2019 – 14:05
Merck KGaA
Merck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Merck, a leading science and technology company, today announced that data from ...
more
11.04.2019 – 07:30
Gerresheimer AG
Gerresheimer makes good start into the new financial year
Duesseldorf (ots) - - Revenues up 6.3% on the prior-year quarter to EUR 308.5m - Adjusted EBITDA at EUR 145.9m in first quarter of 2019 (Q1 2018: EUR 52.6m), comprising of EUR 53.6m plus EUR 92.3m from partial derecognition of contingent purchase price components connected to the Sensile Medical acquisition - Guidance for adjusted EBITDA at constant ...
more
One document
04.03.2019 – 14:01
Novo Nordisk A/S
Ozempic® Superior in Lowering Blood Sugar and Weight Vs Placebo, Both in Combination with SGLT-2 Inhibitors
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this 30 week trial was to assess the efficacy and safety of Ozempic® (semaglutide) 1.0 mg when added to SGLT-2 inhibitor (SGLT-2i) ...
more
18.10.2018 – 09:32
Technische Universität München
Test predicts outcome of hay fever therapies
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35000/ NEWS RELEASE Test predicts outcome of hay fever therapies Allergy researchers look into molecular processes in hyposensitization to pollen Allergen-specific immunotherapy can make everyday life ...
more
11.10.2018 – 12:57
Janssen Pharmaceutica
Janssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology
Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...
more
11.10.2018 – 08:04
Gerresheimer AG
Gerresheimer Increases Revenues by 8.8% and Successfully Integrates Sensile Medical
Düsseldorf, Germany (ots/PRNewswire) - - Revenues at constant exchange rates up 8.8% in third quarter of 2018 to EUR 364.4m - Adjusted EBITDA at constant exchange rates-excluding Sensile Medical and negative effects relating to the exemption from electricity network charges-increased by EUR 1.3m in third quarter to EUR 79.5m - Integration of Sensile Medical proceeding ...
more
11.10.2018 – 07:56
Gerresheimer AG
Gerresheimer increases revenues by 8.8% and successfully integrates Sensile Medical
Düsseldorf (ots) - - Revenues at constant exchange rates up 8.8% in third quarter of 2018 to EUR 364.4m - Adjusted EBITDA at constant exchange rates - excluding Sensile Medical and negative effects relating to the exemption from electricity network charges - increased by EUR 1.3m in third quarter to EUR ...
more
One document
28.09.2018 – 08:41
Novo Nordisk A/S
New Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency
Athens, Greece (ots/PRNewswire) - Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.[1] There are currently no approved ...
more
08.08.2018 – 18:40
Kyowa Kirin International PLC
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
Tokyo (ots/PRNewswire) - - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in previously treated patients based on data showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat. - FDA approval was based ...
more

1